Dr. Bristow Answers Questions
January 26, 2011
Click for questionDrugs or clinical trials for Cancer that seems hormone resistant?
Click for questionWhat has been done to find the cause of cancer?
Click for questionDoes an enlarged prostate lead to prostate cancer?
Click for questionDoes aggresive mean fast growing?
Click for questionPt. 1 Spot in pelvic area?
Click for questionPt. 2 Would he be a candidate for Tookad?
Click for questionDefect in cellular repair?
Click for questionCompare surgery and radio therapy? How many newly diagnosed in GTA? more
Click for questionConnection between your research and urine test?
Click for questionIs the Protein PML part of your work?
Click for questionHow is thiis work funded?
Click for questionWould unlimited funds accelerate the program?
Click for questionIs the project prostate specific?
Click for questionWhat can be expected in the future?
Are there any drugs or clinical trials for Cancer that seems hormone resistant?
Click here to return to top.
What has been done to find the cause of cancer?
Click here to return to top.
Does an enlarged prostate lead to prostate cancer?
Click here to return to top.
Does aggresive mean fast growing?
Click here to return to top.
Pt. 1 Spot in pelvic area?
Click here to return to top.
Pt. 2 Would he be a candidate for Tookad?
Click here to return to top.
Defect in cellular repair?
Click here to return to top.
What is reccurence rate with radio therapy? How many newly diagnosed in GTA?
Click here to return to top.
Connection between your research and urine test?
Click here to return to top.
Is the Protein PML part of your work?
Click here to return to top.
How is thiis work funded?
Click here to return to top.
Would unlimited funds accelerate the program?
Click here to return to top.
Is the project prostate specific?
Click here to return to top.
What can be expected in the future?
Click here to return to top.
Dr. Robert Bristow “Personalized Medicine in Prostate Cancer”
January 26, 2011
On Jan. 26, 2011 Dr. Robert Bristow, gave details of a International Reseach project to PCCN-Toronto’s Awareness Night, prior to it’s public announcement
-The study of cancer genetics is unlocking the secrets of prostate cancer
-These secrets will give rise to new diagnostic tests and new treatments within the next 10 years.
-These will be personal secrets that can be used to individualize treatment for men with prostate cancer.
-and more
Feb. 15, 2011 from CBC News
“Prostate cancer genome to be decoded”
Prostate cancer’s genetic mutations will be mapped under a new $20 million Canadian research project that aims to eventually improve diagnosis and treatment of the disease.
READ MORE
Click here for Dr. Bristow introduction by Winston Klass
Click here for Video Part 1
Click here for Video Part 2
Click here for Video Part 3
Click here for Video Part 4
Click here for complete video.
Click here for Dr. Bristow’s Bio.
Click here for Dr. Bristow Answers Questions
Dr. Bristow introduction by Winston Klass
Part 1 13:48 Minutes
Click here to return to top.
Part 2 13 minutes
Click here to return to top.
Part 3 12:16 minutes
Click here to return to top.
Part 4 11:21 minutes
Click here to return to top.
Complete Presentation 50 minutes
Click here to return to top.
Robert Bristow MD (Toronto, 1992), PhD (Medical Biophysics, Toronto, 1997) FRCPC
Dr. Bristow is currently a Clinician-Scientist and Professor within the Departments of Radiation Oncology and Medical Biophysics at the University of Toronto. He is a Senior Scientist at the Ontario Cancer Institute and a Radiation Oncologist in Genitourinary cancers at the Princess Margaret Hospital (University Health Network).
His primary research interests are in DNA damage response and repair, prostate cancer carcinogenesis and genetic predictors of prostate cancer treatment response. He has active research programs and clinical trials pertaining to hypoxic cell targeting, use of synthetic lethality approaches to cancer treatment and combined molecular targeting with chemotherapy or radiotherapy.
He has leadership roles in:
Co-Director, STTARR Innovation Imaging Facility, MaRS/UHN
Head, Campbell Family Research Institute-PMH Prostate Cancer Research Program
Scientific Board Member, Ontario Cancer Biomarker Network
Chair, Translational Biology Advisory Group for Canadian Association of Radiation Oncology (CARO)
Editor, 4th Edition Basic Science of Oncology
Twice a Canadian Foundation for Innovation (CFI) Awardee
Former Co-Administrator, Canadian Prostate Cancer BioResearch Network
Former Chair, Scientific and Medical Advisory Board and now VP, Strategic Partnerships and Networks, Prostate Cancer Canada.
Lead, Canadian Prostate Cancer Genome Sequencing Project (CPC-GENE)
He has been a member of NCIC and NIH Biomedical Awards Review Panels, the US Army Prostate Program Review Panel, PCRFC, PCF UK, CIHR, KWF-Dutch, CR-UK and MRC UK grants panels.
He has over 200 published papers, abstracts and book chapters and has been an Invited Speaker or Visiting Professor on more than 100 occasions. He was made a Canadian Cancer Society Research Scientist in 2004.
Click here to return to top.